Free tool
FAERS Monitor: Lexiscan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022161 or its brand name (Lexiscan, Regadenoson). Reports on generic versions are filed under their own applications.
Reports
4,773
Serious
2,655
56% of reports
Hospitalization
500
Death reported
130
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea511
- dyspnoea409
- injection site extravasation361
- vomiting358
- headache328
- hypotension315
- cardiac arrest284
- dizziness276
- seizure256
- chest pain233
- blood pressure decreased208
- bradycardia196
- loss of consciousness190
- tremor188
- unresponsive to stimuli164
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 144 |
| 2009 | 104 |
| 2010 | 76 |
| 2011 | 55 |
| 2012 | 425 |
| 2013 | 514 |
| 2014 | 473 |
| 2015 | 301 |
| 2016 | 380 |
| 2017 | 418 |
| 2018 | 424 |
| 2019 | 315 |
| 2020 | 250 |
| 2021 | 175 |
| 2022 | 209 |
| 2023 | 188 |
| 2024 | 155 |
| 2025 | 103 |
| 2026 | 64 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,386 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site extravasationSignal | 361 | 132.8 | 120.1 | 45,734 |
| unresponsive to stimuliSignal | 164 | 28.2 | 24.2 | 4,249 |
| bradycardiaSignal | 196 | 16.3 | 14.2 | 2,805 |
| cardiac arrestSignal | 284 | 15.2 | 13.6 | 3,757 |
| blood pressure decreasedSignal | 208 | 13.8 | 12.1 | 2,464 |
| seizureSignal | 256 | 9.8 | 8.7 | 2,017 |
| hypotensionSignal | 315 | 6.9 | 6.2 | 1,605 |
| loss of consciousnessSignal | 190 | 6.5 | 5.7 | 891 |
| chest painSignal | 233 | 5.5 | 4.9 | 871 |
| tremorSignal | 188 | 5.0 | 4.3 | 601 |
| vomitingSignal | 358 | 3.4 | 3.0 | 603 |
| dyspnoeaSignal | 409 | 3.2 | 2.9 | 627 |
| nauseaSignal | 511 | 2.8 | 2.6 | 634 |
| dizzinessSignal | 276 | 2.4 | 2.2 | 238 |
| headacheSignal | 328 | 2.3 | 2.1 | 249 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.